AFP Clinical Answers

Pulmonary Function Testing, Vulvovaginal Candidiasis, Breast Cancer, Fasting Lipid Levels

 

Am Fam Physician. 2021 May 1;103(9):523.

When is full pulmonary function testing recommended?

Full pulmonary function testing should be performed in patients with a restrictive pattern on spirometry and in patients with a mixed pattern if the forced vital capacity does not improve significantly after administration of a bronchodilator. Bronchoprovocation testing should be performed in patients with normal results on pulmonary function testing but a history that suggests exercise- or allergen-induced asthma.

https://www.aafp.org/afp/2020/0315/p362.html

How effective are probiotics for augmenting antifungal treatment of vulvovaginal candidiasis?

Adding probiotics (typically Lactobacillus species) to antifungal therapy for vulvovaginal candidiasis improves short-term cure rates by 14% and reduces one-month relapse rates by 66% based on a meta-analysis of low-quality randomized controlled trials. Adding probiotics to antifungal therapy for patients with recurrent vulvovaginal candidiasis may improve long-term cure rates over three to six months.

https://www.aafp.org/afp/2020/0401/p432.html

Which patients should be offered medication to reduce the risk of breast cancer?

The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to patients 35 years and older who are at increased risk of breast cancer and at low risk of adverse medication effects. Only tamoxifen is recommended for premenopausal patients. The USPSTF does not endorse any particular risk-prediction tool, and there is no single defined cutoff for increased risk. Numerous risk assessment tools, such as the National Cancer Institute Breast Cancer Risk Assessment Tool (https://bcrisktool.cancer.gov/), estimate a patient's risk of developing breast cancer over the next five years. Patients at increased risk (e.g., at least a 3% risk of breast cancer in the next five years) are likely to derive more benefit than harm from risk-reducing medications.

 

 

Copyright © 2021 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


More in Pubmed

MOST RECENT ISSUE


Sep 2021

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article